FORT WORTH, Texas–(BUSINESS WIRE)–Alcon, the global leader in eye care, today announced the debut of DAILIES® COLORS contact lenses that combine the beauty of eye color enhancement with the convenience of a daily disposable contact lens. The new line…
Author: Business Wire
Avellino Labs Founder Gene Lee Receives 2019 Ellis Island Medal of Honor, Named to World Economic Forum’s Precision Medicine Council
MENLO PARK, Calif.–(BUSINESS WIRE)–Gene Lee, founder of genetic services provider, Avellino Labs, recognized by World Economic Forum and Ellis Island Honors Society.
Global Surgical Eye Care Market Size, Trends, and Forecasts (2019-2023): Dominated by Novartis, Carl Zeiss Stiftung, Johnson & Johnson, and Bausch Health Companies – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Global Surgical Eye Care Market: Size, Trends, Forecasts (2019-2023)” report has been added to ResearchAndMarkets.com’s offering. The global surgical eye care market has observed constant growth in the past few years and projections are made that in the forecasted period (2019-2023) the market would propel with a steady growth rate. The global surgical eye care market would be supported by the growth drivers such as rising incidences of vision impairment disorders,
Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (0.4 Dexamethasone Intracanalicular Insert for Ophthalmic Use) for the Treatment of Ocular Inflammation Following Ophthalmic Surgery
BEDFORD, Mass.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24OCUL&src=ctag" target="_blank">$OCUL</a> <a href="https://twitter.com/hashtag/OCUTX?src=hash" target="_blank">#OCUTX…
Alnylam Announces Progress with RNAi Therapeutics Platform, Including Oral Route of Administration and CNS and Ocular Delivery
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-…
Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WATERTOWN, Mass.–(BUSINESS WIRE)–Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2017 Equity Incentive Plan in accordance with …
Quantum Vision Centers and Eye Surgery Center Provide Notice of Data Security Incident
SWANSEA, IL–(BUSINESS WIRE)–JFJ Eyecare, Ltd, d/b/a Quantum Vision Centers (“Quantum Vision Centers”) and Eye Surgery Center, LLC (“Eye Surgery Center”) are taking action after they became aware of an incident in which some of their systems were acce…
Glaukos Corporation Enters into Definitive Agreement to Acquire DOSE Medical Corporation
SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel ophthalmic surgical devices and sustained pharmaceutical ther…
Alcon Takes Center Stage with Contact Lens Innovations and the iLUX® System at the 2019 Optometry’s Meeting
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon, the global leader in eye care, will launch DAILIES® COLORS contact lenses at the 2019 Optometry’s Meeting, as well as give attendees a preview of PRECISION1™ contact lenses coming soon to the US. These innovat…
EnChroma Expands Leadership Team With Key Hires, Adds Over 100 New Retail Partners in the US, Europe and Canada
BERKELEY, Calif. & ST. LOUIS–(BUSINESS WIRE)–<a href="https://twitter.com/hashtag/colorishere?src=hash" target="_blank">#colorishere</a>–EnChroma Expands Leadership Team with Key Hires, Adds Over 100 New Retail Pa…
Motus GI Bolsters Commercial and Quality/Regulatory Expertise with Two Key Senior Management Additions
FORT LAUDERDALE, Fla.–(BUSINESS WIRE)–Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company dedicated to improving clinical outcomes and enhancing the cost-efficiency of colonoscopy, a…
RIBOMIC annonce les premiers résultats positifs de l'essai clinique de phase 1/2a du RBM-007 (étude SUSHI) chez des patients atteints de dégénérescence maculaire liée à l'âge humide
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., société pharmaceutique de stade clinique spécialisée dans les produits thérapeutiques à aptamères et cotée sur le Mothers Market de la Bourse de Tokyo (numéro de code : 4591), a annoncé aujourd’hui les premiers résultats positifs issus de l’étude SUSHI, étude clinique à dose ascendante unique de Phase 1/2a du RBM-007, aptamère anti-FGF2, chez neuf patients atteints de dégénérescence maculaire liée à l’âge humide (DMLA humide). L’étude SUSHI a atteint le cr
RIBOMIC gibt positive Topline-Ergebnisse der klinischen Phase-1/2a-Studie an RBM-007 (SUSHI-Studie) bei Patienten mit feuchter altersbedingter Makuladegeneration bekannt
TOKIO–(BUSINESS WIRE)–RIBOMIC, Inc., ein auf Aptamer-Therapeutika im klinischen Stadium spezialisiertes Pharmaunternehmen, das am Mothers-Markt der Tokioter Börse gehandelt wird (Börsenkürzel: 4591), gab heute positive Topline-Ergebnisse seiner SUSHI…
Glaucoma Market Spotlight 2019: 10-Year Disease Prevalence Forecast, Licensing and Acquisition Deals, Revenue Forecasts – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Market Spotlight: Glaucoma” report has been added to ResearchAndMarkets.com’s offering. This Market Spotlight report covers the Glaucoma market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts Key Takeaways The author estimates that in 2017, there were 95.5 million prevalen
Global Sunglasses Market Projected to Reach $38.84 Billion by 2024 – Key Players Focus to Leverage Opportunities Posed by Emerging Markets to Expand Their Product Portfolio – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Sunglasses Market – Growth, Trends and Forecasts (2019 – 2024)” report has been added to ResearchAndMarkets.com’s offering. Global sunglasses market is forecasted to reach USD 38.84 billion by 2024 growing at a CAGR of 5.5% during the forecast period (2019-2024). Key Highlights The growth rate of sunglasses is driven by the increased consumer awareness and demand for protection against ultraviolet radiation and glare, as well as the growing popularity of sunglasses
Gymnast Laurie Hernandez and Alcon Help People See Their Potential with New “Eye Can, Eye Will” Campaign
FORT WORTH, Texas–(BUSINESS WIRE)–Alcon, the global leader in eye care, is teaming up with gold- and silver-medal winning gymnast Laurie Hernandez on a new campaign that encourages people to find inspiration to visualize and achieve their goals. The …
Compulink Showcases New User Interface for its Optometry SMART EHR at AOA Optometry’s Meeting 2019
NEWBURY PARK, Calif.–(BUSINESS WIRE)–Compulink showcases new user interface for its optometry SMART EHR at AOA Optometry’s Meeting 2019.
Resumen: RIBOMIC anuncia resultados positivos de la primera línea del ensayo clínico de fase 1/2a de RBM-007 (estudio SUSHI) en sujetos con degeneración macular húmeda relacionada con la edad
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., una compañía farmacéutica en etapa clínica especializada en terapias de aptámeros y cotizada en el Mothers Market de la Bolsa de Tokio (número de código: 4591), ha anunciado hoy los resultados positivos de primera…
Riassunto: RIBOMIC comunica i risultati principali positivi emersi dalla sperimentazione clinica di Fase I/IIa su RBM-007 (studio SUSHI) in soggetti affetti da degenerazione maculare umida dovuta all’invecchiamento
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., un’impresa farmaceutica operante nella fase clinica specializzata in terapie a base di aptameri e quotata presso il Mothers Market della Borsa di Tokyo (codice: 4591), ha comunicato oggi i risultati principali pos…
Samenvatting: RIBOMIC kondigt positieve toplijnresultaten aan van het fase-1/2a klinisch onderzoek van RBM-007 (SUSHI-studie) bij proefpersonen met natte leeftijdsgebonden maculaire degeneratie
TOKYO–(BUSINESS WIRE)–RIBOMIC, Inc., een farmaceutisch bedrijf van het klinische stadium dat zich in aptamertherapie specialiseert en dat op de Mothers Market van de Beurs van Tokyo wordt verhandeld (Codenummer: 4591), kondigde vandaag positieve hoog…